MET-Targeted Therapy

>

Latest News

Multiple Myeloma: Top 10 Advances in the Past 10 Years
Multiple Myeloma: Top 10 Advances in the Past 10 Years

March 28th 2022

Treatment options have expanded widely for patients with multiple myeloma over the past several years, resulting in significantly improved outcomes for these patients.

Tepotinib Induces Durable Responses in MET exon 14 Skipping NSCLC
Tepotinib Induces Durable Responses in MET exon 14 Skipping NSCLC

January 31st 2021

Osimertinib Plus Savolitnib May Address MET Resistance in EGFR+, MET-Amplified NSCLC
Osimertinib Plus Savolitnib May Address MET Resistance in EGFR+, MET-Amplified NSCLC

January 28th 2021

Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine
Increased Attention on Testing for Oncogenic Drivers in NSCLC Advances the Promise of Precision Medicine

December 9th 2020

Safety, Pharmacokinetic Findings Are Revealed for MET Inhibitor TPX-0022
Safety, Pharmacokinetic Findings Are Revealed for MET Inhibitor TPX-0022

December 1st 2020

Video Series
Video Interviews

More News